• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AbbVie (ABBV) Is Up 17.0% After EU MAVIRET Expansion And New Global Label Wins - What's Changed

    Simply Wall St·06/28/2026 00:19:04
    语音播报
    • In June 2026, AbbVie reported a series of regulatory wins, including expanded pediatric indications for SKYRIZI and broader HCV use for MAVIRET in Europe, alongside new aesthetics approvals such as Boey in Canada and SKINVIVE for neck lines in the US.
    • Taken together, these label extensions and launches deepen AbbVie’s reach across immunology, virology and medical aesthetics, widening potential patient pools in several high-need treatment areas.
    • We’ll now examine how the EU expansion of MAVIRET to acute HCV and pediatric patients reshapes AbbVie’s broader investment narrative.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    AbbVie Investment Narrative Recap

    To own AbbVie, you need to be comfortable with a concentrated immunology and neuroscience portfolio, a heavily used balance sheet, and earnings that currently do not cover the dividend. The recent MAVIRET, SKYRIZI and aesthetics approvals are helpful for diversification, but they do not change the near term focus on offsetting HUMIRA erosion, rebuilding margin strength and managing high R&D and deal spending risk.

    Among June’s updates, the EU expansion of MAVIRET to acute and pediatric HCV stands out, as it reinforces AbbVie’s virology presence beyond its core immunology engines. That matters because the biggest question today is whether incremental assets like MAVIRET can meaningfully support the earnings recovery that consensus expects, given the company’s high valuation multiples and reliance on a handful of blockbuster franchises.

    Yet even with these approvals, investors should be aware of the ongoing risk that elevated R&D and acquisition spending...

    Read the full narrative on AbbVie (it's free!)

    AbbVie’s narrative projects $79.0 billion revenue and $22.7 billion earnings by 2029. This requires 7.9% yearly revenue growth and about a $19.1 billion earnings increase from $3.6 billion today.

    Uncover how AbbVie's forecasts yield a $253.55 fair value, in line with its current price.

    Exploring Other Perspectives

    ABBV 1-Year Stock Price Chart
    ABBV 1-Year Stock Price Chart

    Three fair value estimates from the Simply Wall St Community span roughly US$253 to US$434 per share, underlining how far apart individual views can sit. Against that wide range, AbbVie’s dependence on a few blockbuster immunology and neuroscience platforms raises real questions about how resilient future earnings could be if any one pillar stumbles, so it is worth comparing several of these independent viewpoints before deciding how this concentration risk fits your own expectations.

    Explore 3 other fair value estimates on AbbVie - why the stock might be worth just $253.55!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Interested In Other Possibilities?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.